StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3057% below fair value
$0.51−0.02 (-3.73%)

Close on Nov 16, 2026Market cap $78.16MP/E –Yield –

Coherus Oncology total assets

Total assets on the balance sheet at the end of each period.

Coherus Oncology's total assets was $191.18M at Jun 30, 2026. For fiscal 2025 it was $258.34M, down 42.4% from the year before. Over ten years it grew 2.0% a year on average. The highest annual figure on record is $841.65M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$258.34M-42.4%
FY2024Dec 31, 2024$448.53M-28.8%
FY2023Dec 31, 2023$629.60M+30.9%
FY2022Dec 31, 2022$480.85M-29.2%
FY2021Dec 31, 2021$679.33M-19.3%
FY2020Dec 31, 2020$841.65M+105.8%
FY2019Dec 31, 2019$408.93M+311.1%
FY2018Dec 31, 2018$99.47M-38.8%
FY2017Dec 31, 2017$162.61M-8.9%
FY2016Dec 31, 2016$178.49M-16.0%
FY2015Dec 31, 2015$212.38M+13.4%
FY2014Dec 31, 2014$187.22M+294.6%
FY2013Dec 31, 2013$47.45M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$191.18M-56.5%
Q1 FY2026Mar 31, 2026$266.02M-28.3%
Q4 FY2025Dec 31, 2025$258.34M-42.4%
Q3 FY2025Sep 30, 2025$516.52M+2.3%
Q2 FY2025Jun 30, 2025$439.46M-34.9%
Q1 FY2025Mar 31, 2025$371.07M-51.4%
Q4 FY2024Dec 31, 2024$448.53M-28.8%
Q3 FY2024Sep 30, 2024$505.00M-13.5%
Q2 FY2024Jun 30, 2024$674.86M+43.7%
Q1 FY2024Mar 31, 2024$763.55M+89.7%
Q4 FY2023Dec 31, 2023$629.60M+30.9%
Q3 FY2023Sep 30, 2023$583.78M+6.0%
Q2 FY2023Jun 30, 2023$469.59M-14.0%
Q1 FY2023Mar 31, 2023$402.43M-32.2%
Q4 FY2022Dec 31, 2022$480.85M-29.2%
Q3 FY2022Sep 30, 2022$550.91M-25.7%
Q2 FY2022Jun 30, 2022$546.00M-26.2%
Q1 FY2022Mar 31, 2022$593.39M-14.4%
Q4 FY2021Dec 31, 2021$679.33M-19.3%
Q3 FY2021Sep 30, 2021$741.73M-7.7%
Q2 FY2021Jun 30, 2021$739.54M-2.3%
Q1 FY2021Mar 31, 2021$693.30M+48.6%
Q4 FY2020Dec 31, 2020$841.65M+105.8%
Q3 FY2020Sep 30, 2020$803.73M+145.5%
Q2 FY2020Jun 30, 2020$756.61M+214.7%
Q1 FY2020Mar 31, 2020$466.54M+150.7%
Q4 FY2019Dec 31, 2019$408.93M+311.1%
Q3 FY2019Sep 30, 2019$327.38M+131.4%
Q2 FY2019Jun 30, 2019$240.46M+27.7%
Q1 FY2019Mar 31, 2019$186.12M+44.9%
Q4 FY2018Dec 31, 2018$99.47M-38.8%
Q3 FY2018Sep 30, 2018$141.46M-25.5%
Q2 FY2018Jun 30, 2018$188.31M+9.3%
Q1 FY2018Mar 31, 2018$128.46M-43.5%
Q4 FY2017Dec 31, 2017$162.61M-8.9%
Q3 FY2017Sep 30, 2017$189.76M-1.4%
Q2 FY2017Jun 30, 2017$172.25M–
Q1 FY2017Mar 31, 2017$227.50M–
Q4 FY2016Dec 31, 2016$178.49M–
Q3 FY2016Sep 30, 2016$192.36M–

More Coherus Oncology figures

See a number that looks wrong?